Frontier Medicines Corporation
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Frontier Medicines Corporation - overview
Established
2018
Location
South San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2018 by CEO Chris Varma and Daniel Nomura, Frontier Medicines Corporation operates as a biopharmaceutical company that utilizes chemoproteomics to discover and develop therapies that target the binding pockets on proteins and enable them to be accessible for therapeutic intervention. In June 2024, Frontier Medicines Corporation raised USD 20 million in Series C funding from ArrowMark Partners, and Deep Track Capital.. The round was part of a larger USD 100 million series C funding. Frontier Medicines focuses on developing precision-based treatments with an initial emphasis on oncology.
The company’s primary product is a dual KRASG12C inhibitor, designed to target both active and inactive forms of the KRAS mutation. The firm’s approach integrates advanced scientific techniques, including chemoproteomics and machine learning, to build a precision pipeline of medicines. This pipeline aims to address specific cancer-related mutations, improving treatment efficacy and patient outcomes. Frontier Medicines operates from offices in South San Francisco and Boston, supporting their research and development efforts.
The company plans to use its proceeds from June 2024 funding to support its clinical research advancement.
Current Investors
MPM BioImpact, DCVC, Deerfield Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.frontiermeds.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.